1. Home
  2. NTRA vs PSA Comparison

NTRA vs PSA Comparison

Compare NTRA & PSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Natera Inc.

NTRA

Natera Inc.

N/A

Current Price

$378.07

Market Cap

56.7B

Sector

Health Care

ML Signal

N/A

PSA

Public Storage

N/A

Current Price

$334.96

Market Cap

55.2B

Sector

Real Estate

ML Signal

N/A

Company Overview

Basic Information
Metric
NTRA
PSA
Founded
2003
1972
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
56.7B
55.2B
IPO Year
2015
2007

Fundamental Metrics

Financial Performance
Metric
NTRA
PSA
Price
$378.07
$334.96
Analyst Decision
Strong Buy
Hold
Analyst Count
23
22
Target Price
★ $416.39
$330.50
AVG Volume (30 Days)
★ 1.4M
856.2K
Earning Date
11-05-2026
10-26-2026
Dividend Yield
N/A
★ 3.69%
EPS Growth
★ 0.65
N/A
EPS
N/A
★ 6.92
Revenue
$210,939,000.00
★ $4,824,113,000.00
Revenue This Year
$26.22
$5.81
Revenue Next Year
$20.96
$7.92
P/E Ratio
★ N/A
$46.93
Revenue Growth
N/A
★ 2.74
52 Week Low
$181.00
$256.54
52 Week High
$437.41
$335.55

Technical Indicators

Market Signals
Indicator
NTRA
PSA
Relative Strength Index (RSI) 43.12 76.51
Support Level $187.64 $308.79
Resistance Level $437.41 N/A
Average True Range (ATR) 19.55 6.44
MACD -2.75 3.95
Stochastic Oscillator 5.74 97.97

Price Performance

Historical Comparison
NTRA
PSA

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

About PSA Public Storage

Public Storage is the largest owner of self-storage facilities in the US, with more than 3,500 self-storage facilities in 40 states and approximately 259 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage. The company also has a merchandise business, a third-party property management business, and an insurance business that offers products to cover losses for the goods in self-storage facilities.

Share on Social Networks: